NCT05539430View on ClinicalTrials.gov

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 18, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Gastric CancerGastroesophageal-junction CancerEsophageal CancerPancreatic Cancer
Interventions
BIOLOGICAL

LB1908

Claudin 18.2-Targeted autologous Chimeric Antigen Receptor T-cells

Trial Locations (8)

14263

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

33612

RECRUITING

Moffitt Cancer Center, Tampa

37232

RECRUITING

Vanderbilt-Ingram Cancer Center, Nashville

48201

RECRUITING

Karmanos Cancer Institute, Detroit

53226

RECRUITING

Medical College of Wisconsin, Milwaukee

97239

RECRUITING

OHSU Knight Cancer Institute, Portland

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

07601

RECRUITING

John Theurer Cancer Center at HackensackUMC, Hackensack

Sponsors
All Listed Sponsors
lead

Legend Biotech USA Inc

INDUSTRY